Meeting
2011 ASCO Annual Meeting
The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study.
Authors
H. Isayama
University of Tokyo, Tokyo, Japan
H. Isayama , Y. Nakai , T. Sasaki , N. Sasahira , K. Hirano , T. Tsujino , M. Tada , M. Omata , K. Koike
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
UMIN-CTR 000000498
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4040)
Abstract #
4040
Poster Bd #
23H
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Quality Care Symposium
Uptake and effectiveness of FOLFIRINOX for advanced pancreas cancer: A population-based study.
First Author: Safiya Karim
Poster
2017 Gastrointestinal Cancers Symposium
Effect of advanced age, elevated bilirubin, and disease extent on outcomes of unresectable pancreatic cancer (UPC) patients receiving first-line chemotherapy: A population-based study.
First Author: Hannah Marie Cherniawsky
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2022 ASCO Annual Meeting
Do we need postoperative chemotherapy after preoperative FOLFIRINOX in resected borderline or locally advanced pancreatic cancer? A retrospective analysis.
First Author: Roxane Mari